JP2021521264A - 脱毛治療及び発毛促進用組成物 - Google Patents
脱毛治療及び発毛促進用組成物 Download PDFInfo
- Publication number
- JP2021521264A JP2021521264A JP2020568652A JP2020568652A JP2021521264A JP 2021521264 A JP2021521264 A JP 2021521264A JP 2020568652 A JP2020568652 A JP 2020568652A JP 2020568652 A JP2020568652 A JP 2020568652A JP 2021521264 A JP2021521264 A JP 2021521264A
- Authority
- JP
- Japan
- Prior art keywords
- hair loss
- sneeze
- spread
- hair
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 146
- 208000024963 hair loss Diseases 0.000 title claims abstract description 132
- 230000003676 hair loss Effects 0.000 title claims abstract description 121
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000011282 treatment Methods 0.000 title claims description 31
- 230000003779 hair growth Effects 0.000 title abstract description 78
- 239000000284 extract Substances 0.000 claims abstract description 103
- 230000012010 growth Effects 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000002037 dichloromethane fraction Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 14
- -1 patches Substances 0.000 claims description 13
- 230000003752 improving hair Effects 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 231100000360 alopecia Toxicity 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 230000001565 angiopathic effect Effects 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000037390 scarring Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 208000002474 Tinea Diseases 0.000 claims description 2
- 241000130764 Tinea Species 0.000 claims description 2
- 230000001548 androgenic effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000401 methanolic extract Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 64
- 230000015572 biosynthetic process Effects 0.000 abstract description 22
- 230000001737 promoting effect Effects 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 description 63
- 230000000694 effects Effects 0.000 description 56
- 239000000126 substance Substances 0.000 description 37
- 239000013641 positive control Substances 0.000 description 32
- 210000003780 hair follicle Anatomy 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 25
- 238000000605 extraction Methods 0.000 description 23
- 230000003698 anagen phase Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 230000006872 improvement Effects 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000007480 spreading Effects 0.000 description 10
- 238000003892 spreading Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000003658 preventing hair loss Effects 0.000 description 9
- 239000012752 auxiliary agent Substances 0.000 description 8
- 238000011179 visual inspection Methods 0.000 description 8
- 230000003778 catagen phase Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000003797 telogen phase Effects 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229960003632 minoxidil Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- 241000928504 Centipeda minima Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004012 Tofacitinib Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940098804 peridex Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 3
- 229960001350 tofacitinib Drugs 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZNEMGFATAVGQSF-UHFFFAOYSA-N 1-(2-amino-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-5-yl)-2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound NC=1SC2=C(CN(CC2)C(CC=2OC(=NN=2)C=2C=NC(=NC=2)NC2CC3=CC=CC=C3C2)=O)N=1 ZNEMGFATAVGQSF-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 241000208837 Asterales Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000030212 nutrition disease Diseases 0.000 description 2
- 208000019180 nutritional disease Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000003813 thin hair Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241000207961 Sesamum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003051 hair bleaching agent Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008020 response regulators Proteins 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 201000001297 telogen effluvium Diseases 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 210000003135 vibrissae Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
果があるとして知られている。インドでも眼、鼻、歯の痛みに使用する。しかし、発毛効果又は脱毛防止、及び毛髪成長の効能については知られていない。
大韓民国登録特許第10−1810139号
大韓民国登録特許第10−1797667号
米国特許第5,215,894号
本発明のもう一つの目的は、脱毛予防又は改善用食品組成物を提供するものである。
本発明のもう一つの目的は、脱毛予防又は改善用化粧料組成物を提供するものである。
本発明のもう一つの目的は、脱毛予防又は改善用医薬部外品組成物を提供するものである。
本発明のもう一つの目的は、発毛促進用組成物を提供するものである。
本発明のもう一つの目的は、脱毛治療方法を提供するものである。
本発明のもう一つの目的は、脱毛治療のためのさまざまな用途を提供するものである。
、分画物は、抽出液を分画して製造され得る。
liquid chromatography)などのようなさまざまなクロマトグラフィーが挙げられるが、これらに限定されるものではない。
体の種類は、特に制限されず、この技術分野で通常使用される担体であれば、どんなものでも使用することができる。前記担体は、例えば、食塩水、滅菌水、リンゲル液、緩衝食塩水、アルブミン注射液、ラクトース、デキストロース、スクロース、ソルビトール、マンニトール、キシリトール、エリスリトール、マルチトール、マルトデキストリン、グリセロール、エタノールなどが挙げられるが、これに限定されるものではない。前記担体は、単独で使用したり、2種以上を混合して使用したりすることができる。
的な実施例では、本発明の組成物は、1週間から52週間投与することができる。
ラミン酸、サッカリン、ナトリウムなど)、香料(バニリン、ラクトン類等)、膨張剤(ミョウバン、D−酒石酸水素カリウムなど)、強化剤、乳化剤、増粘剤(糊料)、皮膜剤、ガム基礎剤、泡抑制剤、溶剤、および改良剤を挙げられるが、これらに限定されるものではない。前記添加物は、食品の種類に応じて選別され、適切な量で使用することができる。
使用される担体であれば、どんなものでも使用することができる。前記担体は、単独で使用したり、2種以上を混合して使用したりすることができる。
製造例1:トキンソウ抽出液の製造
トキンソウは、2017年8月に忠清北道槐山郡で収穫した乾燥トキンソウ(Centipeda minima)の地上部(購入先:槐山薬草有機農産物協同組合)を2017年9月に購入して試料として使用した。
製造例1で得られたトキンソウ抽出物を減圧して蒸発させ、193.2gの粗抽出液(crude extract)を獲得し、再び800mLの蒸留水に懸濁した。
(800mL×3)、およびn−BuOH(800mL×3)を利用して、極性が増加する順次方向に系統的溶媒分画法を実行して、各分画を減圧濃縮して製造例2(HX(23.0g))、製造例3(CH2Cl2(9.0g))、製造例4(EtOAc(9.0g))及び製造例5(n−BuOH(32.7g))分画物を製造した。
トキンソウは、2018年8月に忠清北道槐山郡で収穫された乾燥トキンソウ(Centipeda minima)の地上部(購入先:槐山薬草有機農産物協同組合)を2018年9月に購入して試料として使用した。
製造例2−5での分画物の製法と同じ方法で製造例6−11のそれぞれの抽出物から順次方向に系統的溶媒分画法を実行し、各分画を減圧濃縮してジクロロメタン分画物を製造した。
製剤例1:トキンソウ抽出物を含む剤形の製造
エタノールとグリセリンとを混合した溶媒(65%:5%)を用いて製造例3のトキンソウ抽出物の含有量が全5%の濃度になるようにトニック剤形の試験物質を調製した。
蒸留水に5%Tween 80と5%グリセリンとを混合した溶媒を用いて製造例6〜17のトキンソウ抽出物又はジクロロメタン分画物のそれぞれを含有量が全20%の濃度になるようにして試験物質を調製した。
トキンソウ抽出物の退行期サプレッサーでの発毛効能試験を進めるためにオスC57BL/6マウス(5週齢)を購入し、1週間馴化し、体重が16〜21gの動物を選定した。脱毛の際、皮膚の損傷が発生した動物又は肌色が黒色の場合には成長期がすでに進行した状態であって、本実験に不向きなため、実験から除外した。
試験群は、それぞれ、正常群、陰性対照群、試験物質投与群、陽性対照群1、2に分離し、正常群と陰性対照群は、それぞれ1匹、試験物質投与群は3匹、陽性対照群1は2匹、陽性対照群2は、1匹に群分離した。具体的には、正常群は溶媒又は試験物質を投与していない群であり、陰性対照群は溶媒のみ投与した群、試験物質群は、製造例3のトキンソウ抽出物を投与した群であり、陽性対照群1は、Minoxidil投与群であり、陽性対照群2は、タンカラック(Litsea glutinosa)抽出物を投与した群である。
製造例3のトニック剤形(製剤例1)を100μL投与量で、一日に2回、6時間間隔で背中の皮膚に7日間塗布し、退行期誘導薬物であるデキサメタゾン(ペリデックス、緑十字)を0.1%、1mLを除毛部位に5日間塗布した。陽性対照群1と2は、5%の濃度で100μlを塗布した。
また、発毛効能目視検査の結果を数値化するために、除毛全部位(溶媒又は試験物質、陽性対照物質塗布部位)で黒色を帯びたり(成長期)、発毛が始まる部位を画像解析プログラム(ImagePro Plus 5.0 、Cybernetics、USA)で画像解析を実施し、%で数値化し、数値化されたデータは、医療統計解析プログラム(Prism 5.0、Graphpad、USA)を利用して数値化されたグラフを作製した。
マウスの皮膚を肉眼で検査した結果、図1、図3及び図4に示すように試験物質投与群は、投与3日目に成長期に移行する傾向がある、他の群に比べてはるかに高く(18.5%、20.4%、32.8%)、陽性対照群1(0.1%、0.3%)及び陽性対照群2(0.4%)では発毛が観察されなかった。投与7日目には、試験物質投与群(84.9%、88.2%、97.0%)で最も優れた発毛効能を確認することができた。
皮膚組織病理学試験は、一般に広く用いられているヘマトキシリン(Hematoxylin)とエオシン(Eosin)を利用したH&E染色で実施し、犠牲にした動物の皮膚組織から試料を採取して固定(fixation)、水洗(washing)、透明(clearing)、パラフィン浸透(paraffin infiltration)、包埋(embedding)、薄切(microtome cutting)、染色(staining)と判読過程を経て、毛包の生成及び発毛現象を確認した。
トキンソウ抽出物の退行期サプレッサーでの発毛効能試験を進行するためにオスC57BL/6マウス(5週齢)を購入し、1週間馴化して、体重が20〜24gの動物を選定した。除毛する際、皮膚の損傷が発生した動物又は肌色が黒色の場合には成長期がすでに進行した状態であって、本実験には不向きなため、実験から除外した。
試験群は、それぞれ、正常群、陰性対照群、試験物質投与群、陽性対照群1、2に分離し、正常群は3匹、陰性対照群は4匹、試験物質投与群はそれぞれ4匹、陽性対照群1(Tofacitinib)は4匹、陽性対照群2(Minoxidil)は4匹に群分離した。具体的には、正常群は溶媒又は試験物質を投与していない群であり、陰性対照群は溶媒のみ投与された群であり、試験物質群は、製造例6、8、9、および11のトキンソウ抽出物(30若しくは100%エタノール、又は30若しくは100%メタノール)をそれぞれ投与した群であり、陽性対照群1は、Tofacitinib群であり、陽性対照群2は、Minoxidilを投与した群である。
マウスの皮膚を肉眼で検査した結果を図6に示した。図6に示すように、試験物質投与群は、投与7日後5日目(+12 day)に成長期に移行する傾向がある、他の群に比べてはるかに高いことを確認した。
皮膚組織病理学試験は、12日目に、一般的に広く使用されるヘマトキシリン(Hematoxylin)とエオシン(Eosin)を利用したH&E染色で実施し、犠牲にされた動物の皮膚組織から試料を採取して固定(fixation)、水洗(washing)、透明(clearing)、パラフィン浸透(paraffin infiltration)、包埋(embedding)、薄切(microtome cutting)、染色(staining)と判読過程を経て、毛包の生成及び発毛現象を確認した。
実施例2と同様の方式で、トキンソウ分画物を用いて脱毛予防、治療、改善、および発
毛促進効果を確認した。
試験物質投与群は、投与7日後5日目(+12 day)に成長期に移行する傾向が他の群に比べてはるかに高いことを、以下の表2に具体的に示した。表2は、投与7日後、5日目のそれぞれの投与群での発毛効能を示す。
皮膚組織病理学試験は、12日目に一般的に広く使用されるヘマトキシリン(Hematoxylin)とエオシン(Eosin)を用いたH&E染色で実施し、犠牲にされた
動物の皮膚組織から試料を採取して固定(fixation)、水洗(washing)、透明(clearing)、パラフィン浸透(paraffin infiltration)、包埋(embedding)、薄切(microtome cutting)、染色(staining)と判読過程を経て、毛包の生成及び発毛現象を確認した。
Claims (15)
- トキンソウ抽出物又はその分画物を含む脱毛予防又は治療用薬剤学的組成物。
- トキンソウ抽出物は、水、炭素数1〜4のアルコール、又はこれらの混合溶媒抽出物であることを特徴とする請求項1に記載の薬剤学的組成物。
- トキンソウ抽出物は、トキンソウメタノール又はエタノール抽出物であることを特徴とする請求項1に記載の薬剤学的組成物。
- トキンソウ抽出物は、トキンソウ10〜90重量%メタノール水溶液抽出物又はトキンソウ10〜90重量%エタノール水溶液抽出物であることを特徴とする請求項3に記載の薬剤学的組成物。
- トキンソウ分画物は、ヘキサン、ジクロロメタンおよび酢酸でなる群から選択されるいずれか一つ以上の分画溶媒の分画物であることを特徴とする請求項1に記載の薬剤学的組成物。
- トキンソウ分画物は、トキンソウジクロロメタン分画溶媒の分画物であることを特徴とする請求項5に記載の薬剤学的組成物。
- トキンソウは、トキンソウの全草であることを特徴とする請求項1に記載の薬剤学的組成物。
- 脱毛は、栄養障害性脱毛、内分泌性脱毛、血管障害性脱毛、壮年性脱毛、結髪性脱毛、円形脱毛、神経性脱毛、非剛性脱毛、トリコチロマニア、悪性脱毛、女性型脱毛、男性型脱毛、アンドロゲン性脱毛、休止期脱毛、頭部白癬、前頭脱毛、減耗症、遺伝性寡毛症、全身薬剤性脱毛、機械的脱毛、外傷性脱毛、圧迫性脱毛、成長期脱毛、非剛性脱毛、毎毒性脱毛、脂漏性脱毛、症候性脱毛、瘢痕性脱毛及び先天性脱毛からなる群から選択される1つ以上であることを特徴とする請求項1に記載の薬剤学的組成物。
- 薬剤学的組成物は、エアロゾル剤、軟膏、液剤、ローション剤、パッチ剤、塗布用粉末、オイル、クリームおよびゲルからなる群から選択されるいずれか一つの剤形であることを特徴とする請求項1に記載の薬剤学的組成物。
- トキンソウ抽出物又はその分画物を含む脱毛予防又は改善用食品組成物。
- トキンソウ抽出物又はその分画物を含む脱毛予防又は改善用化粧料組成物。
- トキンソウ抽出物又はその分画物を含む脱毛予防又は改善用医薬部外品組成物。
- トキンソウ抽出物又はその分画物の治療学的に有効量をこれを必要とする個体に投与する段階を含む脱毛予防又は治療方法。
- 脱毛予防又は治療に使用するためのトキンソウ抽出物又はその分画物を含む組成物。
- 脱毛予防又は治療用薬剤を製造するためのトキンソウ抽出物又はその分画物を含む組成物の用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180024228 | 2018-02-28 | ||
KR10-2018-0024228 | 2018-02-28 | ||
PCT/KR2019/002378 WO2019168348A1 (ko) | 2018-02-28 | 2019-02-27 | 탈모 치료 및 발모 촉진용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021521264A true JP2021521264A (ja) | 2021-08-26 |
Family
ID=67805079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568652A Pending JP2021521264A (ja) | 2018-02-28 | 2019-02-27 | 脱毛治療及び発毛促進用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11351215B2 (ja) |
EP (1) | EP3760214A4 (ja) |
JP (1) | JP2021521264A (ja) |
KR (2) | KR102251495B1 (ja) |
CN (1) | CN112118854A (ja) |
WO (1) | WO2019168348A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023277616A1 (ko) * | 2021-06-30 | 2023-01-05 | 주식회사 디네이쳐 | 중대가리풀 유래의 추출물을 포함하는 탈모기능성 조성물 |
KR102598042B1 (ko) * | 2022-12-05 | 2023-11-03 | 주식회사 디네이쳐 | 중대가리풀 추출물을 포함하는 항염 및 자가면역 질환 예방 및 치료용 조성물 및 이의 제조 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344653A (ja) * | 1999-06-04 | 2000-12-12 | Kanebo Ltd | 活性酸素消去剤及び皮膚化粧料 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3382248A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines |
US5215894A (en) | 1992-02-25 | 1993-06-01 | Merck & Co., Inc. | Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors |
JPH08231353A (ja) * | 1995-03-01 | 1996-09-10 | Shiseido Co Ltd | 養毛料 |
US5804206A (en) | 1997-03-06 | 1998-09-08 | Bio-Botanica, Inc. | Therapeutic composition and method for treating skin using Centipeda cunninghami extract |
JP2000247829A (ja) | 1999-02-24 | 2000-09-12 | Mikimoto Pharmaceut Co Ltd | 化粧料、医薬部外品、医薬品、食品 |
JPWO2005034894A1 (ja) * | 2003-10-09 | 2006-12-21 | 株式会社アドバンジェン | 育毛剤組成物 |
JP5215894B2 (ja) | 2009-02-04 | 2013-06-19 | ルネサスエレクトロニクス株式会社 | 通信制御回路、通信ノード、通信システム、並びに通信制御方法及びプログラム |
CN101518637A (zh) | 2009-04-08 | 2009-09-02 | 苏玉林 | 一种治疗妇女子宫脱垂和肛门脱出的药物及制备方法 |
CN101843658A (zh) | 2010-01-12 | 2010-09-29 | 潘金来 | 脱发生发防脱液 |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
CN110801514A (zh) * | 2011-01-21 | 2020-02-18 | Igisu株式会社 | 秃头症治疗剂 |
KR101810139B1 (ko) | 2011-10-19 | 2017-12-19 | (주)아모레퍼시픽 | 발모 및 육모 촉진용 조성물 |
JP2013136551A (ja) | 2011-12-28 | 2013-07-11 | Kao Corp | ケラチン繊維改質剤 |
CN102824292A (zh) * | 2012-09-22 | 2012-12-19 | 南京正亮医药科技有限公司 | 一种洗发香波 |
KR20140115228A (ko) * | 2013-03-20 | 2014-09-30 | 이장수 | 생약재의 추출물을 유효성분으로 포함하는 탈모 예방 또는 치료용 조성물 |
KR20160074732A (ko) * | 2014-12-17 | 2016-06-29 | 순천향대학교 산학협력단 | 구슬꽃 나무 추출물을 포함하는 피부 미백용 화장료 조성물 |
KR101772486B1 (ko) * | 2015-08-24 | 2017-08-29 | 한국과학기술연구원 | 중머리풀 추출물을 포함하는 신경세포 보호용 조성물 |
KR20170055172A (ko) * | 2015-11-11 | 2017-05-19 | 주식회사 코리아나화장품 | 중머리풀 추출물을 유효성분으로 함유하는 화장료 조성물 |
KR101797667B1 (ko) | 2017-07-24 | 2017-12-12 | 최기남 | 탈모 예방, 개선 또는 치료용 조성물 및 그의 제조방법 |
KR102004366B1 (ko) * | 2017-09-06 | 2019-07-29 | 주식회사 아미코스메틱 | 중대가리풀 추출물을 유효성분으로 함유하는 화장료 조성물 |
-
2019
- 2019-02-27 EP EP19761640.2A patent/EP3760214A4/en not_active Withdrawn
- 2019-02-27 JP JP2020568652A patent/JP2021521264A/ja active Pending
- 2019-02-27 KR KR1020190023403A patent/KR102251495B1/ko active IP Right Review Request
- 2019-02-27 US US16/976,061 patent/US11351215B2/en active Active
- 2019-02-27 CN CN201980015927.3A patent/CN112118854A/zh active Pending
- 2019-02-27 WO PCT/KR2019/002378 patent/WO2019168348A1/ko unknown
-
2021
- 2021-05-06 KR KR1020210058859A patent/KR20210058772A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344653A (ja) * | 1999-06-04 | 2000-12-12 | Kanebo Ltd | 活性酸素消去剤及び皮膚化粧料 |
Also Published As
Publication number | Publication date |
---|---|
EP3760214A1 (en) | 2021-01-06 |
KR102251495B1 (ko) | 2021-05-13 |
WO2019168348A1 (ko) | 2019-09-06 |
US20210138011A1 (en) | 2021-05-13 |
EP3760214A4 (en) | 2021-11-17 |
KR102251495B9 (ko) | 2022-07-20 |
KR20190103983A (ko) | 2019-09-05 |
CN112118854A (zh) | 2020-12-22 |
KR20210058772A (ko) | 2021-05-24 |
US11351215B2 (en) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101743197B1 (ko) | 발효 홍삼을 유효성분으로 함유하는 발모촉진용 두피 케어 샴푸 조성물 제조 방법 및 그 제조 방법에 의해 제조된 샴푸 조성물 | |
KR20200137526A (ko) | 탈모 예방 및 발모 촉진용 조성물 | |
CN107530258B (zh) | 用于促进毛发生长或毛发修复和用于抗炎的组合物 | |
JP6339189B2 (ja) | 発毛および育毛促進用組成物 | |
KR101686008B1 (ko) | 생약 혼합물의 추출물을 함유하는 탈모방지 또는 양모효능이 있는 조성물 | |
KR20210058772A (ko) | 탈모 치료 및 발모 촉진용 조성물 | |
KR100970126B1 (ko) | 탈모방지 및 발모촉진용 조성물의 제조방법 | |
JP2016160198A (ja) | 黒生姜含有組成物 | |
KR102030275B1 (ko) | 모발 세정제 조성물 | |
KR102323101B1 (ko) | 산수국 추출물을 포함하는 모발과 두피 상태 개선용 조성물 | |
US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR102408577B1 (ko) | 자작나무 추출물을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물 | |
CN110248641A (zh) | 包含丝胶、蛇床子提取物及槲寄生提取物的皮肤再生、皮肤舒缓或伤口愈合用组合物 | |
KR20200080556A (ko) | 조팝나무 추출물을 포함하는 피부질환 예방 또는 치료용 조성물 | |
KR20090059445A (ko) | 한약 추출물을 함유하는 양이온/음이온 계면활성제 혼합베시클을 함유하는 탈모 방지용 또는 모발 성장용 조성물 | |
KR20160069919A (ko) | 삼채 추출물을 포함하는 항염증제 | |
KR101742819B1 (ko) | 양모 또는 발모 촉진용 한약재 추출물 및 이를 포함하는 화장료 조성물 | |
KR102129409B1 (ko) | 탈모 치료 및 발모 촉진용 조성물 | |
JP2012025777A (ja) | 血管新生抑制剤及び外用剤 | |
KR20200058730A (ko) | 탈모방지 또는 발모촉진용 조성물 | |
KR20140117064A (ko) | 구증구포 인삼 추출물과 천연 한방 추출물을 함유하는 육모 및 양모 촉진용 화장료 조성물을 이용한 샴푸 및 에센스 | |
KR102168418B1 (ko) | 황칠나무, 황기 및, 두릅나무 복합 추출물을 포함하는 여성 청결제 조성물 | |
KR102209664B1 (ko) | 회잎나무 추출물을 포함하는 피부질환 예방 또는 치료용 조성물 | |
TWI353249B (en) | Hair growth agent composition | |
KR20160071523A (ko) | 지실 추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220315 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230425 |